Self-administered biologics market seen reaching $141.7 billion by 2030

The Business Research Company says the self-administered biologics market will rise from $95.58 billion in 2025 to $141.7 billion by 2030, driven by homecare delivery, self-injection devices and biosimilars. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Self-administered biologics are becoming a bigger part of chronic disease care as patients seek treatment options that reduce clinic visits and give them more control over dosing. - The market's projected growth points to rising demand for at-home therapies across autoimmune disease, diabetes and some cancers. - Growth in home-use biologics could ease pressure on hospitals and infusion centers.

What happened: - The Business Research Company projected the self-administered biologics market will grow from $95.58 billion in 2025 to $103.23 billion in 2026. - The market is forecast to reach $141.7 billion by 2030. - The report said the market will grow at an 8.0% CAGR from 2025 to 2026 and an 8.2% CAGR from 2026 to 2030. - The company published the forecast in its "Self-Administered Biologics Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." View the full report

The details: - Self-administered biologics are biopharmaceutical therapies derived from living organisms that patients can use on their own, usually by injection or infusion at home. - These therapies are used for autoimmune disorders, diabetes and certain cancers. - The report linked historical growth to rising chronic disease rates, more approvals for biologic drugs, expansion of hospital-based infusion treatment, limited convenience in clinical administration and heavy pressure on healthcare facilities. - The report said future growth will be supported by homecare healthcare delivery models, greater adoption of self-injection devices, an expanding biosimilar pipeline, patient preference for treatment autonomy and better subcutaneous biologic formulations. - Emerging trends include more home-based biologic therapies, more patient-centered chronic disease management, wider use of prefilled syringes and autoinjectors, growth in biosimilar self-injectable treatments for autoimmune and metabolic disorders, and stronger regulatory approvals and reimbursement policies for home-use biologics. - The report said North America held the largest market share in 2025. - The report said Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional scope also includes South East Asia, Western Europe, Eastern Europe, South America, and the Middle East and Africa. - The report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report offered a free sample download: Download a free sample

Between the lines: - The forecast suggests biologic treatment is shifting further away from provider-administered care and toward self-managed, at-home use. - Biosimilars, prefilled delivery systems and reimbursement support appear to be the main commercial enablers behind that shift. - Rising rheumatoid arthritis cases reinforce the demand case, especially because autoimmune disease is a key use category for these therapies. - Arthritis Australia reported in February 2024 that 212,136 males and 362,137 females were living with rheumatoid arthritis in 2025, with those figures expected to rise to about 280,040 males and 479,828 females by 2040.

What's next: - The market's growth path now depends on whether homecare models, device adoption and reimbursement policies continue to expand across major regions. - Asia-Pacific's faster growth outlook suggests the next phase of demand may come from broader access and uptake outside North America. - Continued biosimilar launches could widen access and put additional pressure on branded self-injectable biologics.

The bottom line: - Self-administered biologics are moving from niche convenience products to a major global treatment category, with the market now on track to exceed $141.7 billion by 2030.